Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Scherm­afbeelding 2024 03 13 om 20.51.30

Biointelect and CR2O forge strategic partnership to provide advanced end-to-end commercialisation solutions for the life-science sector

, 13 March 2024/in E-News /by panglobal

Australian, European and U.S. clients are now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/Scherm­afbeelding-2024-03-13-om-20.51.30.jpg 604 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-13 19:52:212024-03-13 19:52:21Biointelect and CR2O forge strategic partnership to provide advanced end-to-end commercialisation solutions for the life-science sector
Capricorn

Capricorn Scientific and ExcellGene form strategic partnership to support biotech industries

, 13 March 2024/in E-News /by panglobal

Capricorn Scientific and ExcellGene have established a strategic partnership within the biotechnology sector. Applying their collective expertise and capabilities, the collaboration seeks to help customers by optimizing processes, developing products, and offering solutions in biotechnology. The partnership is dedicated to customeroriented solutions and a commitment to excellence, with the aim of advancing biotech research, development, […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/Capricorn.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-13 19:48:222024-03-13 19:48:22Capricorn Scientific and ExcellGene form strategic partnership to support biotech industries
PharmaKure

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Disease

, 12 March 2024/in E-News /by panglobal

PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, will collaborate with Sheffield Hallam University in the field of epigenetics. The partnership will focus on ‘gene-based environmental biomarkers’ – epigenetic markers – for calculating risk scores for Alzheimer’s diseases. Together with PharmaKure’s blood-based biomarker, ALZmetrix https://bitly.ws/3eZTQ, this […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/PharmaKure.jpg 683 1024 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-12 15:30:292024-03-12 15:30:29PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Disease
shutterstock 1821340823

Johnson & Johnson to acquire Ambrx to advance nextgen antibody drug conjugates for cancer treatment

, 12 March 2024/in E-News /by panglobal

Johnson & Johnson has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2 billion, or $1.9 billion net of estimated cash acquired.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/03/shutterstock_1821340823.jpg 950 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-03-12 15:27:432024-03-12 15:27:43Johnson & Johnson to acquire Ambrx to advance nextgen antibody drug conjugates for cancer treatment
A centrifuged blood

Getting the most from every drop – new advances in blood separation

, 8 February 2024/in E-News, Featured Articles /by 3wmedia

Getting the most from every drop – new advances in blood separation Alexandra Sommer, Senior Product Manager, Clinical Diagnostics at Tecan

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/02/A-centrifuged-blood.png 250 290 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2024-02-08 08:32:022024-08-22 08:33:00Getting the most from every drop – new advances in blood separation
240107Feb OGT celebrates opening of new facility

OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships

, 8 February 2024/in E-News /by panglobal

OGT, a leading global provider of genomic research and diagnostic solutions, proudly announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. 

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/02/240107Feb-OGT-celebrates-opening-of-new-facility.jpg 1090 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-02-08 08:09:192024-02-08 08:09:19OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships
shutterstock 2314449325

Meet ‘Coscientist’ – your new super-efficient AI lab partner

, 18 January 2024/in E-News /by panglobal

In less time than it will take you to read this article, an artificial intelligence-driven system was able to autonomously learn about certain Nobel Prize-winning chemical reactions and design a successful laboratory procedure to make them. The AI did all that in just a few minutes – and nailed it on the first try.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_2314449325.jpg 1281 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-18 09:37:222024-01-18 09:45:48Meet ‘Coscientist’ – your new super-efficient AI lab partner
shutterstock 1902146578

PrecisionLife project awarded Innovate UK Grant to improve diagnosis and treatment of ME/CFS and long Covid

, 17 January 2024/in E-News /by panglobal

Leading computational biology company PrecisionLife, which is driving precision medicine in complex chronic diseases, the ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh, have been awarded a £622,000 (about US$794,000) grant by Innovate UK’s Advancing Precision Medicine programme […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_1902146578.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 14:21:572024-01-17 14:31:37PrecisionLife project awarded Innovate UK Grant to improve diagnosis and treatment of ME/CFS and long Covid
shutterstock 1496330648

ANTABIO raises €25 million for phase 2 next-gen antibacterial study

, 17 January 2024/in E-News /by panglobal

Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, has raised €25 million in a Series B financing round, which will enable the company to complete the phase 2 clinical studies of MEM-ANT3310, a next generation antibacterial.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_1496330648.jpg 1047 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 14:18:042024-01-17 14:18:04ANTABIO raises €25 million for phase 2 next-gen antibacterial study
shutterstock 530971462

Metrion Biosciences closes £3.5m new equity financing to expand Cambridge laboratories

, 17 January 2024/in E-News /by panglobal

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, has secured £3.5 million (about US$3,19 million) in new equity financing, including £2.5m from lead investor Maven Capital Partners and £1 million from existing investor, Gresham House Ventures. The funding will be used to further expand Metrion’s laboratories in Cambridge, UK, invest in specialist […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2024/01/shutterstock_530971462.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2024-01-17 14:15:052024-01-17 14:15:05Metrion Biosciences closes £3.5m new equity financing to expand Cambridge laboratories
Page 26 of 227«‹2425262728›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription